Isoflavones and green kiwifruit : a pilot study assessing the effects on bone turnover and lipid profile in healthy postmenopausal New Zealand women : a thesis presented in partial fulfilment of the requirements for the degree of Master of Science in Physiology at Massey University, Palmerston North, New Zealand
Loading...
Date
2014
DOI
Open Access Location
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Massey University
Rights
The Author
Abstract
Background: The reduction in estrogen synthesis during menopause heightens the risk
of development of osteoporosis and cardiovascular disease in postmenopausal
women. Isoflavone (daidzein and genistein) interventions in postmenopausal women
have reduced bone loss, and improved the serum lipid profile, which may reduce the
risk of fracture and incidence of cardiovascular disease. However, skeletal benefits are
inconsistent across interventions. This is partly a result of population heterogeneity in
enteric bacterial daidzein metabolism – only ~30% of Caucasian women produce
equol, a daidzein metabolite. Equol is more bioactive than its precursor and equol
producers have more consistently shown skeletal benefits from isoflavone
supplementation. Few interventions have accounted for equol production in
postmenopausal study populations. Additionally, there is limited knowledge on how
prebiotic foods, such as green kiwifruit, modulate daidzein-metabolising bacteria and
equol production in humans. This pilot study aimed to assess bone turnover in
response to isoflavone supplementation, and to determine the proportion of equol
producers in postmenopausal women.
Objectives: The main objective was to measure the effect of short-term daily
isoflavone supplementation alone or with the addition of green kiwifruit on
biochemical markers of bone resorption, urinary deoxypyridinoline, plasma crosslinked
C-terminal telopeptide of type I collagen, and plasma undercarboxylated
osteocalcin in postmenopausal Caucasian women. A secondary objective was to
measure the effect of isoflavones and kiwifruit on serum lipid profile. Additionally,
equol production was determined in this population and assessed as a main effect.
Methods: This randomised crossover pilot study recruited 33 healthy postmenopausal
Caucasian women, 1-10 years postmenopausal, and randomly allocated participants to
treatment group A (n=16) or B (n=17) for a 16-week intervention. There were two
consecutive 6-week treatment periods with a 2-week lead-in period at intervention
commencement and a 2-week washout period between treatments. These treatments
prescribed either: (1) daily isoflavone supplementation (50 mg/day aglycone daidzein
and genistein) alone or (2) with two green kiwifruit. Group A and B completed both
treatments in opposite order. At treatment baseline and endpoints the following were
measured (four time points): bone markers, serum lipid profile and both serum and
urinary daidzein and equol. The hormones, serum follicle stimulating hormone,
estradiol and thyroid-stimulating hormone, were also measured at baseline and
endpoint to monitor potential adverse effects of isoflavones.
Results: Equol producers made up 30% of this study population (equol producers
n=10; non-equol producers n=30). Serum equol rose significantly in equol producers.
Plasma undercarboxylated osteocalcin decreased by 15.5% after the kiwifruit and
isoflavone treatment and increased by 10.8% after the isoflavone only treatment.
There were no changes in plasma C-terminal telopeptide of type I collagen or urinary
deoxypyridinoline. In non-equol producers high-density lipoprotein cholesterol
declined by an average of 4.9% with each treatment; there was no change in serum
high-density lipoprotein cholesterol in equol producers following isoflavone treatment
alone, and an 8.3% increase in serum high-density lipoprotein cholesterol following the
combined kiwifruit and isoflavone combined. There were no other changes to the lipid
parameters or hormones.
Conclusions: An aglycone isoflavone dose of 50 mg/day did not reduce bone
resorption in the postmenopausal women in this study. Kiwifruit consumption
decreased plasma undercarboxylated osteocalcin levels possibly due to the vitamin K
content of green kiwifruit; however, alternative bioactive components in kiwifruit may
have modulated this effect. The isoflavone treatment inhibited a decline in serum
high-density lipoprotein cholesterol in equol producers and had synergistic effect with
kiwifruit, which increasing this parameter. Equol and the carotenoid lutein from green
kiwifruit may potentially modulate systemic inflammation. Kiwifruit may have a
prebiotic effect in equol producers as shown by the increase in log ratio of daidzein to
equol, but this requires further study. This equol producer subgroup was too small to
detect a change the markers of bone resorption. Larger long-term studies are required
to delineate the skeletal and cardiovascular effects of isoflavones and equol
production in postmenopausal women.
Description
Keywords
Kiwifruit in nutrition, Osteoporosis prevention, Post-menopausal women, Bone turnover, Isoflavones